Carlos A. Roca-Gomez

Toulouse, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 95 publications

Simlukafusp alfa (FAP-IL2v) plus atezolizumab with or without bevacizumab in unresectable, metastatic renal cell carcinoma: a randomized, open-label phase Ib study.

Simlukafusp alfa (FAP-IL2v) plus atezolizumab with or without bevacizumab in unresectable, metastatic renal cell carcinoma: a randomized, open-label phase Ib study.

Journal: Journal for immunotherapy of cancer

Published: February 02, 2026

Innovative Research Organization to Facilitate Clinical Trials Implementation in the Era of Molecular Oncology: The Spiderweb Model of the Oncodistinct Network.

Innovative Research Organization to Facilitate Clinical Trials Implementation in the Era of Molecular Oncology: The Spiderweb Model of the Oncodistinct Network.

Journal: JCO precision oncology

Published: January 21, 2026

Lenvatinib plus Pembrolizumab for Patients with Previously Treated Advanced Gastric, Biliary Tract, or Pancreatic Cancer: Results from the Phase II LEAP-005 Study.

Lenvatinib plus Pembrolizumab for Patients with Previously Treated Advanced Gastric, Biliary Tract, or Pancreatic Cancer: Results from the Phase II LEAP-005 Study.

Journal: Cancer research communications

Published: January 14, 2026

A Phase 1 dose-escalation study to evaluate safety, pharmacokinetics, and pharmacodynamics of OSE-279, an anti-PD-1 monoclonal antibody in patients with advanced solid tumours.

A Phase 1 dose-escalation study to evaluate safety, pharmacokinetics, and pharmacodynamics of OSE-279, an anti-PD-1 monoclonal antibody in patients with advanced solid tumours.

Journal: European journal of cancer (Oxford, England : 1990)

Published: January 02, 2026

Pan-tumor activity of olomorasib, a next-generation KRAS G12C inhibitor in KRAS G12C-mutant advanced solid tumors: a first-in-human study.

Pan-tumor activity of olomorasib, a next-generation KRAS G12C inhibitor in KRAS G12C-mutant advanced solid tumors: a first-in-human study.

Journal: Nature communications

Published: July 28, 2025

HPV circulating tumor DNA to monitor response to pembrolizumab and vorinostat combination in patients with advanced HPV-related squamous-cell carcinomas.

HPV circulating tumor DNA to monitor response to pembrolizumab and vorinostat combination in patients with advanced HPV-related squamous-cell carcinomas.

Journal: ESMO open

Published: June 06, 2025

First-in-human phase 1 dose-escalation study of W0180, an anti-VISTA monoclonal antibody, with and without pembrolizumab in patients with locally advanced or metastatic solid tumours.

First-in-human phase 1 dose-escalation study of W0180, an anti-VISTA monoclonal antibody, with and without pembrolizumab in patients with locally advanced or metastatic solid tumours.

Journal: BMJ oncology

Published: May 19, 2025

Lenvatinib Plus Pembrolizumab for Patients With Previously Treated Advanced Colorectal Cancer: Results From the Phase II LEAP-005 Study.

Lenvatinib Plus Pembrolizumab for Patients With Previously Treated Advanced Colorectal Cancer: Results From the Phase II LEAP-005 Study.

Journal: Clinical colorectal cancer

Published: March 31, 2025

Addressing screening failures in early-phase clinical trials in oncology: impact on patient outcomes and strategies for improvement.

Addressing screening failures in early-phase clinical trials in oncology: impact on patient outcomes and strategies for improvement.

Journal: ESMO open

Published: January 29, 2025

ESMO-Magnitude of Clinical Benefit Scale version 2.0 (ESMO-MCBS v2.0).

ESMO-Magnitude of Clinical Benefit Scale version 2.0 (ESMO-MCBS v2.0).

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: December 21, 2024

Tumor-localized CD40 agonism with MP0317, a FAP x CD40 DARPin, reprograms the tumor microenvironment in patients with advanced solid tumors: an open-label, nonrandomized, dose-escalation phase 1 study.

Tumor-localized CD40 agonism with MP0317, a FAP x CD40 DARPin, reprograms the tumor microenvironment in patients with advanced solid tumors: an open-label, nonrandomized, dose-escalation phase 1 study.

Journal: Nature cancer

Published: December 20, 2024

Effect of prior and first-line immunotherapy on baseline immune biomarkers and modulation of the tumor microenvironment in response to nivolumab and relatlimab combination therapy in patients with melanoma from RELATIVITY-020.

Effect of prior and first-line immunotherapy on baseline immune biomarkers and modulation of the tumor microenvironment in response to nivolumab and relatlimab combination therapy in patients with melanoma from RELATIVITY-020.

Journal: Journal for immunotherapy of cancer

Published: December 02, 2024

Showing 1-12 of 95

Last Updated: 09/26/2026